{
  "items": "29",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Ensysce Biosciences enrolls first patient in phase 3 pain drug trial",
      "url": "https://au.investing.com/news/company-news/ensysce-biosciences-enrolls-first-patient-in-phase-3-pain-drug-trial-93CH-4162554",
      "time_published": "20251212T020903",
      "authors": [
        "Investing.com"
      ],
      "summary": "Ensysce Biosciences has enrolled its first patient in a pivotal Phase 3 clinical trial for PF614, a drug designed for moderate to severe pain with abuse-deterrent properties. Despite this milestone for the micro-cap pharmaceutical company (NASDAQ: ENSC), its stock price has fallen significantly, experiencing an 80% year-to-date decline. The trial will evaluate PF614's efficacy and safety in post-surgical pain relief, using the company's TAAP and MPAR platforms to engineer safeguards against misuse.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
      "source": "Investing.com Australia",
      "category_within_source": "General",
      "source_domain": "Investing.com Australia",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913508"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.709477"
        }
      ],
      "overall_sentiment_score": 0.111426,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.109728",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid",
      "url": "https://www.8newsnow.com/business/press-releases/accesswire/1115759/ensysce-biosciences-achieves-major-milestone-with-initiation-of-enrollment-in-pivotal-phase-3-trial-of-pf614-its-next-generation-opioid",
      "time_published": "20251210T050842",
      "authors": [
        "NULL"
      ],
      "summary": "Ensysce Biosciences has begun enrolling patients in its pivotal Phase 3 clinical trial (PF614-301) for PF614, a next-generation opioid designed to provide potent pain relief with built-in abuse protection. This study aims to demonstrate PF614's efficacy for post-surgical pain and its safety features, including a twice-daily dosing regimen to reduce blood drug concentration fluctuations. The trial marks a significant step towards commercialization for Ensysce, offering a potentially safer opioid treatment for severe pain.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1115759",
      "source": "KLAS 8 News Now",
      "category_within_source": "General",
      "source_domain": "KLAS 8 News Now",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.906006"
        }
      ],
      "overall_sentiment_score": 0.485875,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "0.959057",
          "ticker_sentiment_score": "0.493003",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Should You Buy Ensysce Biosciences After Share Sale?",
      "url": "https://stockstotrade.com/news/ensysce-biosciences-inc-ensc-news-2025_12_09/",
      "time_published": "20251209T200933",
      "authors": [
        "Tim Bohen",
        "Ben Sturgill",
        "Ellis Hobbs"
      ],
      "summary": "Ensysce Biosciences Inc. (NASDAQ: ENSC) saw its stock decline by 16.25% after filing to sell 4.6 million shares, raising concerns about potential dilution despite the company's commitment to innovation in drug development. The biotech firm faces profitability challenges, with a negative EBIT margin and negative cash flow, though its dedication to R&D and potential FDA drug approvals offer long-term promise for patient investors.",
      "banner_image": "https://content.stockstotrade.com/wp-content/uploads/2025/12/volatile-biotech-stock-market-trends.png",
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.908308"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.820297"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.932604"
        }
      ],
      "overall_sentiment_score": -0.295795,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.275732",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences (NASDAQ: ENSC) starts Phase 3 PF614 trial in abuse-deterrent opioid",
      "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-achieves-major-milestone-with-initiation-of-bn5jl2vdgk0b.html",
      "time_published": "20251209T130933",
      "authors": [
        "NULL"
      ],
      "summary": "Ensysce Biosciences has enrolled the first patient in its pivotal Phase 3 trial (PF614-301) for PF614, an abuse-deterrent opioid designed for moderate to severe post-abdominoplasty pain. This multicenter, randomized, double-blind study aims to evaluate twice-daily dosing for consistent analgesia and reduced abuse/overdose risks. Despite this clinical milestone, the company's stock experienced a negative market reaction, aligning with a pattern of selling into what are perceived as positive operational updates due to potential dilution or funding concerns.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1115759",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.610862"
        }
      ],
      "overall_sentiment_score": -0.237958,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.218482",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid",
      "url": "https://www.corsicanadailysun.com/national/ensysce-biosciences-achieves-major-milestone-with-initiation-of-enrollment-in-pivotal-phase-3-trial-of/article_d066272c-f704-58c7-865a-a24b755aaf6d.html",
      "time_published": "20251209T130933",
      "authors": [
        "NULL"
      ],
      "summary": "Ensysce Biosciences has initiated enrollment in its pivotal Phase 3 clinical trial for PF614, a next-generation opioid designed to provide potent pain relief with built-in abuse protection. This trial, named \"A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of PF614 for the Treatment of Moderate to Severe Pain after Abdominoplasty,\" aims to demonstrate PF614's ability to deliver consistent post-surgical pain relief while reducing abuse risk. The company believes PF614 represents a significant advance in safer opioid therapy.",
      "banner_image": "NULL",
      "source": "Corsicana Daily Sun",
      "category_within_source": "General",
      "source_domain": "Corsicana Daily Sun",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.909407"
        }
      ],
      "overall_sentiment_score": 0.449941,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.419651",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid",
      "url": "https://fox40.com/business/press-releases/accesswire/1115759/ensysce-biosciences-achieves-major-milestone-with-initiation-of-enrollment-in-pivotal-phase-3-trial-of-pf614-its-next-generation-opioid",
      "time_published": "20251209T130933",
      "authors": [
        "NULL"
      ],
      "summary": "Ensysce Biosciences has announced the initiation of enrollment in its pivotal Phase 3 clinical trial for PF614, a next-generation opioid designed for potent pain relief with built-in abuse protection. The trial, PF614-301, will evaluate the efficacy and safety of PF614 for moderate to severe post-surgical pain. This milestone marks a significant step towards commercialization and aims to provide a safer opioid alternative.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1115759",
      "source": "FOX40 News",
      "category_within_source": "General",
      "source_domain": "FOX40 News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.931897"
        }
      ],
      "overall_sentiment_score": 0.4932,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.495466",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid",
      "url": "https://fox59.com/business/press-releases/accesswire/1115759/ensysce-biosciences-achieves-major-milestone-with-initiation-of-enrollment-in-pivotal-phase-3-trial-of-pf614-its-next-generation-opioid",
      "time_published": "20251209T080000",
      "authors": [
        "NULL"
      ],
      "summary": "Ensysce Biosciences has initiated enrollment in its pivotal Phase 3 clinical trial for PF614, a next-generation opioid designed to provide potent pain relief with built-in abuse protection. This trial, PF614-301, will evaluate the efficacy and safety of PF614 for moderate to severe pain after abdominoplasty, emphasizing reduced abuse risk through its innovative chemical mechanism. The company aims to redefine pain care by offering safer opioid therapy with consistent pain control and protective features.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1115759",
      "source": "Fox 59",
      "category_within_source": "General",
      "source_domain": "Fox 59",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925756"
        }
      ],
      "overall_sentiment_score": 0.489134,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.459652",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid",
      "url": "https://fox2now.com/business/press-releases/accesswire/1115759/ensysce-biosciences-achieves-major-milestone-with-initiation-of-enrollment-in-pivotal-phase-3-trial-of-pf614-its-next-generation-opioid",
      "time_published": "20251209T030906",
      "authors": [],
      "summary": "Ensysce Biosciences has initiated enrollment for its pivotal Phase 3 clinical trial of PF614, a next-generation opioid designed for potent pain relief with built-in abuse protection. This trial, PF614-301, will evaluate the efficacy and safety of PF614 for moderate to severe post-abdominoplasty pain, aiming to provide a safer treatment option through its unique abuse-deterrent properties and twice-daily dosing. The company believes PF614 represents a significant step towards commercialization and a new standard for opioid safety.",
      "banner_image": "https://i0.wp.com/fox2now.com/wp-content/uploads/sites/14/2025/12/AP25293526090277.jpg?w=2000&ssl=1",
      "source": "FOX 2",
      "category_within_source": "General",
      "source_domain": "FOX 2",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.490203,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.454761",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology",
      "url": "https://fox2now.com/business/press-releases/accesswire/1113613/ensysce-biosciences-announces-broader-patent-protection-for-groundbreaking-mparr-overdose-protection-technology",
      "time_published": "20251206T050842",
      "authors": [
        "NULL"
      ],
      "summary": "Ensysce Biosciences has secured a new U.S. patent for its MPAR\u00ae (Multi-Pill Abuse Resistance) technology, extending protection through 2042. This patent reinforces the company's intellectual property for its overdose protection platform, which has already received Breakthrough Therapy Designation from the FDA. The MPAR technology aims to prevent excessive opioid delivery while maintaining pain relief, and Ensysce is also exploring its application in other drug classes.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1113613",
      "source": "FOX 2",
      "category_within_source": "General",
      "source_domain": "FOX 2",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.912580"
        }
      ],
      "overall_sentiment_score": 0.458228,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.474753",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ensysce (NASDAQ: ENSC) secures MPAR overdose tech patent protection to 2042",
      "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-announces-broader-patent-protection-for-awy1s6ibradr.html",
      "time_published": "20251203T035216",
      "authors": [
        "NULL"
      ],
      "summary": "Ensysce Biosciences announced it has received a U.S. Notice of Allowance for a new patent covering its MPAR\u00ae overdose protection technology, extending its intellectual property coverage through 2042. This patent, covering both composition-of-matter and method-of-use claims, strengthens the company's position, especially given MPAR's Breakthrough Therapy Designation from the FDA in January 2025. Clinical trials with PF614-MPAR have shown effective pain relief and reduced excessive opioid delivery, and Ensysce is expanding the technology to other drug classes.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1113613",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925350"
        },
        {
          "topic": "finance",
          "relevance_score": "0.703508"
        }
      ],
      "overall_sentiment_score": 0.504236,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.518211",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology",
      "url": "https://www.abc4.com/business/press-releases/accesswire/1113613/ensysce-biosciences-announces-broader-patent-protection-for-groundbreaking-mparr-overdose-protection-technology",
      "time_published": "20251203T035216",
      "authors": [
        "NULL"
      ],
      "summary": "Ensysce Biosciences has secured a new U.S. patent for its MPAR\u00ae (Multi-Pill Abuse Resistance) technology, extending protection through 2042. This patent enhances their intellectual property for overdose protection, which earned FDA Breakthrough Therapy Designation in January 2025. The technology aims to minimize abuse and overdose risks across various drug classes, including opioids, amphetamines, and methadone.",
      "banner_image": "https://www.nxsttv.com/wp-content/uploads/2022/08/ANW_COLOR_FULL_VECTOR.png?w=300",
      "source": "ABC4 Utah",
      "category_within_source": "General",
      "source_domain": "ABC4 Utah",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925401"
        }
      ],
      "overall_sentiment_score": 0.464161,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.484250",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs",
      "url": "https://www.kron4.com/business/press-releases/accesswire/1102929/ensysce-biosciences-secures-4-million-financing-unlocking-up-to-20-million-in-total-financing-to-advance-breakthrough-pain-programs",
      "time_published": "20251117T080500",
      "authors": [
        "NULL"
      ],
      "summary": "Ensysce Biosciences secured $4 million in convertible preferred stock financing, with the potential for an additional $16 million, to advance its pain management programs. This funding will accelerate the Phase 3 clinical development of PF614, an analgesic candidate, with market readiness projected within 18-24 months. The company aims to provide safer, abuse- and overdose-resistant options for severe pain through its innovative TAAP and MPAR platforms.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1102929",
      "source": "KRON4",
      "category_within_source": "General",
      "source_domain": "KRON4",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.845737"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.707920"
        }
      ],
      "overall_sentiment_score": 0.528897,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.526252",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences (NASDAQ: ENSC) closes $4M round, unlocking $16M for PF614 Phase 3",
      "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-secures-4-million-financing-unlocking-up-to-20-puw85dyxneq6.html",
      "time_published": "20251117T080500",
      "authors": [
        "NULL"
      ],
      "summary": "Ensysce Biosciences (NASDAQ: ENSC) has closed a $4.0 million convertible preferred financing round with the potential for an additional $16.0 million over the next 24 months, totaling up to $20.0 million. This funding will accelerate the Phase 3 development of their lead analgesic candidate, PF614, with market readiness expected within 18-24 months. The financing terms include a fixed conversion price of $2.50 per share for the initial tranche and 50% warrant coverage, indicating strong investor confidence despite potential shareholder dilution.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1102929",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.934880"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.818726"
        }
      ],
      "overall_sentiment_score": 0.103721,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.138285",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences (NASDAQ: ENSC) begins Phase 3 PF614 trial; Q3 net loss $3.7M",
      "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-reports-third-quarter-2025-financial-i87g1et6tn6v.html",
      "time_published": "20251117T035216",
      "authors": [
        "NULL"
      ],
      "summary": "Ensysce Biosciences initiated a pivotal Phase 3 PF614 trial, highlighting progress for its next-generation opioid therapeutics aimed at minimizing abuse and overdose risk. The company reported a Q3 2025 net loss of $3.7 million but secured $4 million in convertible preferred stock financing with potential for an additional $16 million. Key advancements include FDA Breakthrough Therapy designation support for PF614-MPAR and engagement of Rho, Inc. to conduct the pivotal study, signaling positive clinical momentum despite financial losses.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.924968"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.833081"
        },
        {
          "topic": "finance",
          "relevance_score": "0.605577"
        }
      ],
      "overall_sentiment_score": 0.103665,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.135512",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences Reports Increased R&D Expenses Amid Net Loss",
      "url": "https://www.tipranks.com/news/company-announcements/ensysce-biosciences-reports-increased-rd-expenses-amid-net-loss",
      "time_published": "20251117T035216",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Ensysce Biosciences, Inc. (ENSC) reported increased operating expenses and a net loss for Q3, primarily due to heightened research and development activities for its abuse and overdose-resistant pain medications. The company's total operating expenses rose to $10.6 million for the nine months ending September 30, 2025, resulting in a net loss of $7.4 million despite $3.2 million in federal grants. Ensysce remains committed to advancing its PF614 and PF614-MPAR product candidates and is actively exploring additional funding opportunities.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1096459574-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.909857"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.922000"
        }
      ],
      "overall_sentiment_score": 0.114625,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.140368",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences\u2019 Innovative Approach to Safer Opioid Use: A Clinical Study Update",
      "url": "https://www.tipranks.com/news/company-announcements/ensysce-biosciences-innovative-approach-to-safer-opioid-use-a-clinical-study-update",
      "time_published": "20251102T111028",
      "authors": [
        "TipRanks Clinical-Trials-Auto-Generated Newsdesk"
      ],
      "summary": "Ensysce Biosciences (ENSC) announced an update on its clinical study evaluating PF614, an oxycodone prodrug, with Nafamostat Mesylate to prevent oxycodone conversion in overdose situations. The study, which began on July 8, 2024, aims to assess the pharmacokinetics of oxycodone in both immediate-release and extended-release formulations. This research is significant for developing safer opioid use and could positively impact Ensysce Biosciences' stock performance.",
      "banner_image": null,
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.927330"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.635153"
        }
      ],
      "overall_sentiment_score": 0.416376,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.389294",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Standing-Room-Only: 400 Pain Experts Review Ensysce's Revolutionary Overdose-Proof Opioid Technology",
      "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-showcases-urgent-need-for-safer-opioids-at-pain-m1rhw0tyvwq0.html",
      "time_published": "20250904T080000",
      "authors": [],
      "summary": "Ensysce Biosciences hosted a symposium at PAINWeek 2025, titled \"Pain Management, RE-Invented: A New Era for Analgesia,\" showcasing its TAAP\u2122 and MPAR\u00ae technologies to approximately 400 attendees. The event highlighted Ensysce's approach to developing safer opioids, featuring its lead candidate PF614, which uniquely uses the body's chemistry to activate pain relief while preventing overdose. Dr. William Schmidt presented data on PF614 and outlined plans for an upcoming Phase 3 trial in acute post-surgical pain, emphasizing the potential for superior analgesia and overdose protection.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.441191,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "0.990499",
          "ticker_sentiment_score": "0.430897",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds",
      "url": "https://www.yourcentralvalley.com/business/press-releases/accesswire/1019324/ensysce-biosciences-inc-announces-closing-of-exercise-of-warrants-for-2-2-million-gross-proceeds/",
      "time_published": "20250424T161500",
      "authors": [],
      "summary": "Ensysce Biosciences, Inc. (NASDAQ: ENSC) has announced the closing of the exercise of certain outstanding warrants, generating approximately $2.2 million in gross proceeds. These proceeds will be used for the continued development of its TAAP\u2122 and MPAR\u00ae programs and for working capital. The company also issued new unregistered warrants for additional shares of common stock.",
      "banner_image": "https://i0.wp.com/www.yourcentralvalley.com/wp-content/uploads/sites/54/2025/12/image_624b7e.png?w=2000&ssl=1",
      "source": "www.yourcentralvalley.com",
      "category_within_source": "General",
      "source_domain": "www.yourcentralvalley.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.824162"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.918791"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.706035"
        }
      ],
      "overall_sentiment_score": 0.34388,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.331685",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ENSC\u2019s Future Brightens: A Swing to Watch?",
      "url": "https://stockstotrade.com/news/ensysce-biosciences-inc-ensc-news-2025_04_23/",
      "time_published": "20250424T092700",
      "authors": [
        "Tim Bohen",
        "Ben Sturgill",
        "Ellis Hobbs"
      ],
      "summary": "Ensysce Biosciences Inc. (ENSC) stock has surged by 92.36% due to positive FDA designations and promising clinical trial results for its overdose protection drug PF614-MPAR. Despite recording significant operational losses and negative profitability ratios, the company's high gross margin and moderate short-term liquidity suggest strategic positioning for future growth, fueled by recent funding and investor interest in pharmaceutical breakthroughs.",
      "banner_image": null,
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.927926"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.940213"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.807960"
        }
      ],
      "overall_sentiment_score": 0.458308,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.451523",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences secures patent for OUD treatment",
      "url": "https://www.investing.com/news/company-news/ensysce-biosciences-secures-patent-for-oud-treatment-93CH-3998468",
      "time_published": "20250423T081200",
      "authors": [
        "Investing.com"
      ],
      "summary": "Ensysce Biosciences Inc. (NASDAQ:ENSC) has received a Notice of Allowance for a patent on a new opioid use disorder (OUD) treatment, PF9001, from the U.S. Patent and Trademark Office. This medication uses the company's TAAP\u2122 and MPAR\u00ae technologies to reduce the risks associated with traditional methadone therapy. The company has also recently concluded Part 1 of its second clinical trial for PF614-MPAR, another novel opioid medication, and raised $1.1 million through a stock sale to support its programs.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.704618"
        }
      ],
      "overall_sentiment_score": 0.427077,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.422381",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Revolutionary Opioid Treatment Patent Promises Safer Alternative to Methadone: Key Advantages Revealed",
      "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-receives-u-s-patent-for-groundbreaking-treatment-sprp4u5cmn66.html",
      "time_published": "20250423T080000",
      "authors": [],
      "summary": "Ensysce Biosciences has received a U.S. patent for PF9001, a novel opioid use disorder (OUD) treatment designed to be a safer alternative to methadone by incorporating abuse deterrence and overdose protection technologies. This new drug shows reduced cardiotoxicity potential and offers once-daily dosing with prolonged effects, addressing critical limitations of current OUD therapies. The research is supported by the National Institute on Drug Abuse, highlighting its potential to improve treatment outcomes for OUD patients.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.402046,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.401106",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven?",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ensc/ensysce-biosciences/news/when-will-ensysce-biosciences-inc-nasdaqensc-breakeven-1",
      "time_published": "20250312T000000",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage pharmaceutical company, is projected to break even in 2026, according to two industry analysts. The company, which posted an US$8.0m loss in its most recent financial year, is expected to turn a profit of US$24m in 2026, driven by an anticipated 93% year-on-year growth rate. Analysts express high confidence in this growth, and the company maintains a prudent capital structure with low debt.",
      "banner_image": null,
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.921187"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.930260"
        }
      ],
      "overall_sentiment_score": 0.304835,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "0.996883",
          "ticker_sentiment_score": "0.334919",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ENSC stock touches 52-week low at $0.36 amid market challenges",
      "url": "https://uk.investing.com/news/company-news/ensc-stock-touches-52week-low-at-036-amid-market-challenges-93CH-3674001",
      "time_published": "20240830T173000",
      "authors": [
        "Investing.com"
      ],
      "summary": "Ensysce Biosciences Inc. (ENSC) stock has fallen to a new 52-week low of $0.36, reflecting significant market challenges and a broader downturn in the biotech sector. Despite recent financial developments like a $5 million offering and a $14 million NIH grant, the company faces declining revenue and weak gross profit margins. InvestingPro suggests caution but notes the company holds more cash than debt and its fair value estimate is $0.6, potentially indicating undervaluation.",
      "banner_image": null,
      "source": "Investing.com UK",
      "category_within_source": "General",
      "source_domain": "Investing.com UK",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.928971"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.802025"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.736239"
        }
      ],
      "overall_sentiment_score": -0.407732,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.402448",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Ensysce stock jumps on $14M federal grant (NASDAQ:ENSC)",
      "url": "https://seekingalpha.com/news/4144105-ensysce-wins-14m-federal-grant-for-lead-pain-therapy?source=feed_symbol_ENSC",
      "time_published": "20240827T084300",
      "authors": [
        "Dulan Lokuwithana"
      ],
      "summary": "Ensysce Biosciences (ENSC) saw its stock jump by approximately 62% in premarket trading after securing a $14 million federal grant. The grant from the U.S. government will support the investigation of its lead pain therapy candidate, PF614-MPAR. This significant funding boosted investor confidence in the nano-cap biotech company.",
      "banner_image": null,
      "source": "Seeking Alpha",
      "category_within_source": "General",
      "source_domain": "Seeking Alpha",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.912459"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.831229"
        },
        {
          "topic": "economy_fiscal",
          "relevance_score": "0.740278"
        }
      ],
      "overall_sentiment_score": 0.740242,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.743502",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023",
      "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-to-chair-the-fierce-new-product-planning-summit-v4i4l9fetapv.html",
      "time_published": "20231003T081500",
      "authors": [],
      "summary": "Ensysce Biosciences (NASDAQ: ENSC) announced that its Chief Commercial Officer, Geoff Birkett, will chair and deliver opening remarks at the Fierce New Product Planning Summit 2023 in Boston on October 16-17, 2023. Birkett will also present a case study on best practices for launching new drug products. The summit focuses on informed, value-based, data-driven decisions for products in the life science pipeline.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.237252,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.202750",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference",
      "url": "https://www.stocktitan.net/news/ENSC/biosciences-to-present-at-the-h-c-wainwright-25th-annual-global-zuz30z8orxf4.html",
      "time_published": "20230905T081500",
      "authors": [],
      "summary": "Ensysce Biosciences (NASDAQ: ENSC) announced that its management will present at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023, in New York, NY. CEO Dr. Lynn Kirkpatrick and CFO Dave Humphrey will discuss their 'Next Generation' analgesics and Phase 3 development plans, and will be available for one-on-one meetings. A webcast of the presentation will also be available for interested parties.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.732577"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.908045"
        }
      ],
      "overall_sentiment_score": 0.105279,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.124474",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium",
      "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-to-present-clinical-dataset-at-major-pain-week-wf06dt5d3a69.html",
      "time_published": "20230814T081500",
      "authors": [],
      "summary": "Ensysce Biosciences (NASDAQ: ENSC) announced it will host a luncheon symposium and present recent clinical data at PAINWeek on September 7-8, 2023, in Las Vegas, NV. The symposium will feature leading authorities discussing current severe pain treatment, drug use and abuse, and the safety and effectiveness of Ensysce's next-generation opioid agents, PF614 and PF614-MPAR. The company's CEO, Dr. Lynn Kirkpatrick, will introduce the satellite symposium focusing on severe pain and next-generation solutions, including their MPAR\u00ae opioid overdose protection technology.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.945221"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.647323"
        }
      ],
      "overall_sentiment_score": 0.001614,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "0.328485",
          "ticker_sentiment_score": "0.024914",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences Announces IRB Approval of Key Study Protocol",
      "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-announces-irb-approval-of-key-study-1ftm4uje4yw1.html",
      "time_published": "20230808T081500",
      "authors": [],
      "summary": "Ensysce Biosciences announced that its Investigational Review Board (IRB) has approved the protocol for a new study, PF614-201, designed to assess the time of onset for severe pain relief by PF614. This study, to be conducted in Kansas, marks a significant step towards the full Phase 3 evaluation of PF614, a chemically modified opioid product aiming to improve prescription drug safety. The company anticipates results by late 2023, further supporting the drug's potential as a safer option for severe pain management.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.938023"
        }
      ],
      "overall_sentiment_score": 0.342631,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.321476",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study",
      "url": "https://finance.yahoo.com/news/ensysce-biosciences-announces-completion-enrollment-120500718.html",
      "time_published": "20230322T120500",
      "authors": [],
      "summary": "Ensysce Biosciences has completed enrollment for the final stage of its Phase 1 study, PF614-MPAR-101, for an opioid overdose protection pain product. This groundbreaking product, PF614-MPAR, is designed to reduce oxycodone release at excess doses, offering built-in protection against abuse and overdose, as reported by Dr. Maria Bermudez and Ensysce CEO Dr. Lynn Kirkpatrick. The study has shown an exceptional safety profile, and further data, particularly pharmacokinetic data, is expected in Q2 2023.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.918610"
        }
      ],
      "overall_sentiment_score": 0.457622,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENSC",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.486797",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}